MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562025 | Name: NBI-31772
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NBI-31772 is an potent insulin-like growth factor-1 binding protein (IGFBP) inhibitor.

Chemical Structure

NBI-31772
NBI-31772
CAS#374620-70-9

Theoretical Analysis

MedKoo Cat#: 562025

Name: NBI-31772

CAS#: 374620-70-9

Chemical Formula: C17H11NO7

Exact Mass: 341.0536

Molecular Weight: 341.28

Elemental Analysis: C, 59.83; H, 3.25; N, 4.10; O, 32.82

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
25mg USD 1,250.00 2 Weeks
500mg USD 4,250.00 2 Weeks
1g USD 6,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NBI-31772; NBI 31772; NBI31772;
IUPAC/Chemical Name
1-(3,4-Dihydroxybenzoyl)-6,7-dihydroxy-3-isoquinolinecarboxylic acid
InChi Key
ZCMFEWUYBFMLIN-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H11NO7/c19-11-2-1-7(4-12(11)20)16(23)15-9-6-14(22)13(21)5-8(9)3-10(18-15)17(24)25/h1-6,19-22H,(H,24,25)
SMILES Code
O=C(C1=CC2=C(C(C(C3=CC=C(O)C(O)=C3)=O)=N1)C=C(O)C(O)=C2)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
NBI-31772 is the potent and nonselective inhibitor of IGFBP with a Ki value of 47 nM.
In vitro activity:
In this study, the role of Igfbps in oocyte maturation was investigated in zebrafish. By treatment of an Igfbps inhibitor NBI-31772 in vitro, the oocyte maturation could be stimulated in a clear dose-, time- and stage-dependent manner. Reference: Gen Comp Endocrinol. 2019 Sep 15;281:83-90. https://pubmed.ncbi.nlm.nih.gov/31170402/
In vivo activity:
To assess the involvement of IGFBP-3 in maternal motivation, IGF-I and NBI-31772, a non-peptide ligand inhibitor of IGFBP-3, were continuously administered intracerebroventricularly (i.c.v.) via osmotic minipumps implanted in rat mothers on the 2nd postpartum day. Prolonged intracerebroventricular injection of IGF-I or antagonism of brain IGFBP-3 with an inhibitor (NBI-31772) using osmotic minipumps increased pup retrieval time, suggesting reduced maternal motivation. Reference: Sci Rep. 2017 Jun 13;7(1):3396. https://pubmed.ncbi.nlm.nih.gov/28611445/
Solvent mg/mL mM
Solubility
DMF 30.0 87.91
DMSO 59.7 174.96
Ethanol 10.0 29.30
PBS (pH 7.2) 0.1 0.41
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 341.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Li J, Wang Y, Kang T, Li X, Niu C. Insulin-like growth factor binding proteins inhibit oocyte maturation of zebrafish. Gen Comp Endocrinol. 2019 Sep 15;281:83-90. doi: 10.1016/j.ygcen.2019.06.002. Epub 2019 Jun 3. PMID: 31170402. 2. Safian D, van der Kant HJG, Crespo D, Bogerd J, Schulz RW. Follicle-Stimulating Hormone Regulates igfbp Gene Expression Directly or via Downstream Effectors to Modulate Igf3 Effects on Zebrafish Spermatogenesis. Front Endocrinol (Lausanne). 2017 Nov 20;8:328. doi: 10.3389/fendo.2017.00328. PMID: 29209278; PMCID: PMC5702253. 3. Lékó AH, Cservenák M, Szabó ÉR, Hanics J, Alpár A, Dobolyi Á. Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. Sci Rep. 2017 Jun 13;7(1):3396. doi: 10.1038/s41598-017-03645-5. PMID: 28611445; PMCID: PMC5469809. 4. Safian D, Morais RD, Bogerd J, Schulz RW. Igf Binding Proteins Protect Undifferentiated Spermatogonia in the Zebrafish Testis Against Excessive Differentiation. Endocrinology. 2016 Nov;157(11):4423-4433. doi: 10.1210/en.2016-1315. Epub 2016 Sep 30. PMID: 27689414.
In vitro protocol:
1. Li J, Wang Y, Kang T, Li X, Niu C. Insulin-like growth factor binding proteins inhibit oocyte maturation of zebrafish. Gen Comp Endocrinol. 2019 Sep 15;281:83-90. doi: 10.1016/j.ygcen.2019.06.002. Epub 2019 Jun 3. PMID: 31170402. 2. Safian D, van der Kant HJG, Crespo D, Bogerd J, Schulz RW. Follicle-Stimulating Hormone Regulates igfbp Gene Expression Directly or via Downstream Effectors to Modulate Igf3 Effects on Zebrafish Spermatogenesis. Front Endocrinol (Lausanne). 2017 Nov 20;8:328. doi: 10.3389/fendo.2017.00328. PMID: 29209278; PMCID: PMC5702253.
In vivo protocol:
1. Lékó AH, Cservenák M, Szabó ÉR, Hanics J, Alpár A, Dobolyi Á. Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. Sci Rep. 2017 Jun 13;7(1):3396. doi: 10.1038/s41598-017-03645-5. PMID: 28611445; PMCID: PMC5469809. 2. Safian D, Morais RD, Bogerd J, Schulz RW. Igf Binding Proteins Protect Undifferentiated Spermatogonia in the Zebrafish Testis Against Excessive Differentiation. Endocrinology. 2016 Nov;157(11):4423-4433. doi: 10.1210/en.2016-1315. Epub 2016 Sep 30. PMID: 27689414.
1: Rinker TE, Philbrick BD, Hettiaratchi MH, Smalley DM, McDevitt TC, Temenoff JS. Microparticle-mediated sequestration of cell-secreted proteins to modulate chondrocytic differentiation. Acta Biomater. 2017 Dec 30. pii: S1742-7061(17)30804-8. doi: 10.1016/j.actbio.2017.12.038. [Epub ahead of print] PubMed PMID: 29292168. 2: Safian D, van der Kant HJG, Crespo D, Bogerd J, Schulz RW. Follicle-Stimulating Hormone Regulates igfbp Gene Expression Directly or via Downstream Effectors to Modulate Igf3 Effects on Zebrafish Spermatogenesis. Front Endocrinol (Lausanne). 2017 Nov 20;8:328. doi: 10.3389/fendo.2017.00328. eCollection 2017. PubMed PMID: 29209278; PubMed Central PMCID: PMC5702253. 3: Lékó AH, Cservenák M, Szabó ÉR, Hanics J, Alpár A, Dobolyi Á. Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. Sci Rep. 2017 Jun 13;7(1):3396. doi: 10.1038/s41598-017-03645-5. PubMed PMID: 28611445; PubMed Central PMCID: PMC5469809. 4: Safian D, Morais RD, Bogerd J, Schulz RW. Igf Binding Proteins Protect Undifferentiated Spermatogonia in the Zebrafish Testis Against Excessive Differentiation. Endocrinology. 2016 Nov;157(11):4423-4433. Epub 2016 Sep 30. PubMed PMID: 27689414. 5: Choi WY, Gemberling M, Wang J, Holdway JE, Shen MC, Karlstrom RO, Poss KD. In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration. Development. 2013 Feb 1;140(3):660-6. doi: 10.1242/dev.088526. PubMed PMID: 23293297; PubMed Central PMCID: PMC3561784. 6: Hollis ER 2nd, Lu P, Blesch A, Tuszynski MH. IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury. Exp Neurol. 2009 Jan;215(1):53-9. doi: 10.1016/j.expneurol.2008.09.014. Epub 2008 Oct 2. PubMed PMID: 18938163; PubMed Central PMCID: PMC2632606. 7: Schertzer JD, Gehrig SM, Ryall JG, Lynch GS. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol. 2007 Oct;171(4):1180-8. Epub 2007 Sep 6. PubMed PMID: 17823291; PubMed Central PMCID: PMC1988868. 8: Khawaja XZ. Development of a scintillation proximity assay for human insulin-like growth factor-binding protein 4 compatible with inhibitor high-throughput screening. Anal Biochem. 2007 Jul 1;366(1):80-6. Epub 2007 Mar 18. PubMed PMID: 17482135. 9: Malberg JE, Platt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE, Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007 Nov;32(11):2360-8. Epub 2007 Mar 7. PubMed PMID: 17342171. 10: Silha JV, Murphy LJ. The effects of the insulin-like growth factor-I aptamer, NBI-31772, on glucose homeostasis in the mouse. Can J Physiol Pharmacol. 2005 Jul;83(7):557-63. PubMed PMID: 16091781. 11: De Ceuninck F, Caliez A, Dassencourt L, Anract P, Renard P. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res Ther. 2004;6(5):R393-403. Epub 2004 Jun 28. PubMed PMID: 15380039; PubMed Central PMCID: PMC546277. 12: Mackay KB, Loddick SA, Naeve GS, Vana AM, Verge GM, Foster AC. Neuroprotective effects of insulin-like growth factor-binding protein ligand inhibitors in vitro and in vivo. J Cereb Blood Flow Metab. 2003 Oct;23(10):1160-7. PubMed PMID: 14526226. 13: Liu XJ, Xie Q, Zhu YF, Chen C, Ling N. Identification of a nonpeptide ligand that releases bioactive insulin-like growth factor-I from its binding protein complex. J Biol Chem. 2001 Aug 31;276(35):32419-22. Epub 2001 Jul 9. PubMed PMID: 11445558.